NeurAxis, Inc.

AMEX:NRXS

Biotechnology

Healthcare
$4.61 +4.25%

+$0.29 today

Market cap
$65.43M
Beta
1.41
P/E (TTM)
-10.5
EPS (TTM)
-$0.67
52W Low $2.20High $9.33

Volume 0.21M

Average 0.18M

Returns on capital

NeurAxis, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-229.5%

avg 106.7%

ROIC

-204.7%

avg 117.4%

ROA

-121.8%

avg -670.1%

Analysis

ROA is currently the strongest return metric at -121.8% versus its period average of -670.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Brian Carrico

President, Chief Executive Officer & DirectorUSD 547.6K44——

Timothy Robert Henrichs

Chief Financial OfficerUSD 489.42K539.53K0.08%

Thomas Carrico

Chief Regulatory Officer and Compliance & Privacy OfficerUSD 400.58K69——

Adrian Miranda

Senior Vice President of Science & Technology and Chief Medical OfficerUSD 399.07K560<0.01%

Craig Blanchard

Chief Commercial Officer————

Trisha Baumgardt

Vice President of Marketing————

Ryan Kuhlman

Vice President of Sales————

Behnam Shamsian

Investor Relations————

Christopher Robin Brown

Founder, Director of Innovation & Director—72792.84K6.40%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 8, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

9

$1.43M

Sells

0

$0.00

Net Transaction Value

+$1.43M

Net buying

Most Active

Carrico Brian Allen

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 8, 26

Carrico Brian Allen

Direct

Buy$1.3K
Oct 8, 26

Carrico Thomas Joeseph

Direct

Buy$1.6K
Oct 8, 26

Henrichs Timothy Robert

Direct

Buy$9.4K
Apr 1, 26

Carrico Brian Allen

Direct

Buy$15.8K
Apr 1, 26

Carrico Thomas Joeseph

Direct

Buy$1.3K
Apr 1, 26

Henrichs Timothy Robert

Direct

Buy$14.9K
Feb 12, 26

Hannasch Brian

Direct

Buy$196.8K
Feb 11, 26

Hannasch Brian

Direct

Buy$186K
Dec 23, 25

Aharon Gil

Indirect

Buy$1M

Summary

Insiders reported 9 buys worth $1.43M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.43M. Carrico Brian Allen was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+10.0%
+103.3% (3yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at +10.0% over three years. Forward estimates point to Revenue at +103.3% (3yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does NeurAxis, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NRXS's management, answered from reported figures.

Who manages NRXS?

NeurAxis, Inc. (NRXS) lists 9 active executives. The top listed executive is Adrian Miranda, Senior Vice President of Science & Technology and Chief Medical Officer.

Are NRXS insiders buying or selling?

Recent insider activity shows net buying of $2.92M.